Detailed Narrative
Q1 FY26 Performance Overview
Rossari Biotech reported a steady Q1 FY26 with revenue from operations growing 11.0% YoY to Rs. 543.7 crore. EBITDA for the quarter stood at Rs. 67.9 crore, up 4.6% YoY, resulting in an EBITDA margin of 12.5%, down from 13.3% in the same quarter last year. Excluding the institutional and B2C business, which reported a loss of approximately Rs. 7 crore, the adjusted EBITDA was Rs. 75 crore, growing 12% YoY with an adjusted margin of about 16%.
Segmental Performance & Challenges
Top-line growth was primarily driven by healthy momentum in the HPPC and AHN segments. However, the export business faced headwinds due to prevailing global uncertainties, impacting Agri and Textile segments, leading to some delayed shipments. The institutional and B2C business reported a loss of Rs. 7 crore in Q1, though management expects significant improvement and potential break-even by the end of FY26 or FY27. The textile chemicals business saw volume growth YoY, but value was impacted by export delays.
Capacity Expansion & Raw Material Outlook
Capacity expansion projects across Rossari Biotech, Unitop Chemicals, and Tristar Intermediates are progressing well, with phased commissioning expected in coming quarters. These investments are projected to generate 3x-4x asset turns at optimal utilizations over the medium term⏳. Q1 production was temporarily impacted by 10-12 days of intermittent shutdowns for CAPEX activities. The enhanced Ethylene Oxide (EO) supply from Reliance is anticipated by September-October 2026, and Rossari expects to achieve 100% capacity utilization by FY28, ramping up over 3-4 years.
International Expansion Strategy
As part of its international strategy, Rossari is establishing an overseas formulation facility in Southeast Asia to serve as a strategic hub for the region. This initial investment is modest, estimated between Rs. 15 crore and Rs. 20 crore. This facility aims to enable quicker turnaround times, improved delivery schedules, and tailored solutions for customers, strengthening the company's global footprint and customer engagement.
Financial Outlook & Guidance
For the next two years, management expects a mid-double-digit growth of 14%-15% for both top line and EBITDA. FY26 is characterized as a year of consolidation and capability building. The company aims to maintain margin stability this year, although it remains cautious due to ongoing pricing challenges and the potential need to pass on raw material price reductions. Exports are projected to contribute around 27%-28% of the overall turnover on an annualized basis.
Institutional Cleaning Business Focus
The Institutional Cleaning and Consumer Business, which includes pet care, reported revenues of Rs. 159 crore in FY24 and Rs. 276 crore in FY25. Despite a softer Q1 performance and a reported loss of approximately Rs. 7 crore, management is optimistic about healthy growth on an annual basis. The target is for this business to at least break even on an annualized EBITDA basis by the end of FY26, and definitely by FY27, with gross margins typically ranging between 28% and 30%.